Update on treatments for premature ejaculation

International Journal of Clinical Practice

Volumn 65, Issue 1, 2011, Pages 16-26

  Hellstrom, W J G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; DAPOXETINE; EMLA; ESCITALOPRAM; FLUOXETINE; LIDOCAINE; PAROXETINE; PRILOCAINE; SERTRALINE; TRAMADOL;

DRUG APPROVAL; DRUG EFFICACY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; MALE; PAIN; PRACTICE GUIDELINE; PREMATURE EJACULATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANALGESICS, OPIOID; ANESTHETICS, LOCAL; BENZYLAMINES; EJACULATION; HUMANS; LIDOCAINE; MALE; NAPHTHALENES; PHOSPHODIESTERASE 5 INHIBITORS; PRILOCAINE; SEROTONIN AGENTS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TRAMADOL;

EID: 78650496092     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02479.x     Document Type: Review

References (63)

1. Laumann EO, Paik A, Rosen RC,. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537-44.
2. Dunn KM, Croft PR, Hackett GI,. Sexual problems: a study of the prevalence and need for health care in the general population. Fam Pract 1998; 15: 519-24.
3. Reading AE, Wiest WM,. An analysis of self-reported sexual behavior in a sample of normal males. Arch Sex Behav 1984; 13: 69-83.
4. Rowland D, Perelman M, Althof S, et al. Self-reported premature ejaculation and aspects of sexual functioning and satisfaction. J Sex Med 2004; 1: 225-32.
5. Simons JS, Carey MP,. Prevalence of sexual dysfunctions: results from a decade of research. Arch Sex Behav 2001; 30: 177-219.
6. Aschka C, Himmel W, Ittner E, Kochen MM,. Sexual problems of male patients in family practice. J Fam Pract 2001; 50: 773-8.
7. Metz ME, Pryor JL, Nesvacil LJ, et al. Premature ejaculation: a psychophysiological review. J Sex Marital Ther 1997; 23: 3-23.
8. Frank E, Anderson C, Rubinstein D,. Frequency of sexual dysfunction in 'normal' couples. N Engl J Med 1978; 299: 111-5.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, 2000.
10. McMahon CG, Althof SE, Waldinger MD, et al. An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. BJU Int 2008; 102: 338-50.
11. Morales A, Barada J, Wyllie MG,. A review of the current status of topical treatments for premature ejaculation. BJU Int 2007; 100: 493-501.
12. Waldinger MD,. Recent advances in the classification, neurobiology and treatment of premature ejaculation. Adv Psychosom Med 2008; 29: 50-69.
13. Bartoletti R, Mondaini N, Pavone C, et al. Introduction to chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). Arch Ital Urol Androl 2007; 79: 55-7.
14. El-Nashaar A, Shamloul R,. Antibiotic treatment can delay ejaculation in patients with premature ejaculation and chronic bacterial prostatitis. J Sex Med 2007; 4: 491-6.
15. Trinchieri A, Magri V, Cariani L, et al. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome. Arch Ital Urol Androl 2007; 79: 67-70.
16. El-Sakka AI,. Association of risk factors and medical comorbidities with male sexual dysfunctions. J Sex Med 2007; 4: 1691-700.
17. El-Sakka AI,. Premature ejaculation in non-insulin-dependent diabetic patients. Int J Androl 2003; 26: 329-34.
18. Cihan A, Demir O, Demir T, et al. The relationship between premature ejaculation and hyperthyroidism. J Urol 2009; 181: 1273-80.
19. Montague DK, Jarow J, Broderick GA, et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004; 172: 290-4.
20. Sharlip I,. Rational use of dapoxetine for the treatment of premature ejaculation. Neuropsychopharmacology 2008; 33: 2785.
21. Mulhall JP,. Current and future pharmacotherapeutic strategies in treatment of premature ejaculation. Urology 2006; 67: 9-16.
22. Powell JA, Wyllie MG,. 'Up and coming' treatments for premature ejaculation: progress towards an approved therapy. Int J Impot Res 2009; 21: 107-15.
23. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH,. The majority of men with lifelong premature ejacuation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. J Sex Med 2007; 4: 1028-37.
24. Hellstrom WJ,. Emerging treatments for premature ejaculation: focus on dapoxetine. Neuropsychiatr Dis Treat 2009; 5: 37-46.
25. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B,. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004; 16: 369-81.
26. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F,. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62 (Suppl. 3): 10-21.
27. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997; 23: 176-94.
28. Bolton JM, Sareen J, Reiss JP,. Genital anaesthesia persisting six years after sertraline discontinuation. J Sex Marital Ther 2006; 32: 327-30.
29. Csoka AB, Bahrick A, Mehtonen OP,. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J Sex Med 2008; 5: 227-33.
30. Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol 2002; 5: 147-51.
31. Hammad TA, Laughren T, Racoosin J,. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332-9.
32. Buvat J, Tesfaye F, Rothman M, et al. Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009; 55: 957-67.
33. Giuliano F, Levine SB, Buvat J, et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials [Abstracts of the 23rd Annual European Association of Urology Congress. March 26-29, 2008. Milan, Italy]. Eur Urol Suppl 2008; 7: 187.
34. Kaufman JM, Rosen RC, Mudumbi RV, et al. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int 2009; 103: 651-8.
35. Pryor JL, Althof SE, Steidle C, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006; 368: 929-37.
36. McMahon C, Kim SW, Park NC, et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 2009; 7: 256-68.
37. Safarinejad MR,. Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology 2008; 33: 1259-65.
38. Safarinejad MR,. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clin Neuropharmacol 2006; 29: 243-52.
39. Waldinger MD,. Premature ejaculation: definition and drug treatment. Drugs 2007; 67: 547-68.
40. Waldinger MD, Schweitzer DH, Olivier B,. On-demand SSRI treatment of premature ejaculation: pharmacodynamic limitations for relevant ejaculation delay and consequent solutions. J Sex Med 2005; 2: 121-31.
41. Arafa M, Shamloul R,. A randomized study examining the effect of 3 SSRI on premature ejaculation using a validated questionnaire. Ther Clin Risk Manag 2007; 3: 527-31.
42. Safarinejad MR,. Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol 2007; 27: 444-50.
43. Xin ZC, Chung WS, Choi YD, et al. Penile sensitivity in patients with primary premature ejaculation. J Urol 1996; 156: 979-81.
44. Atikeler MK, Gecit I, Senol FA,. Optimum usage of prilocaine-lidocaine cream in premature ejaculation. Andrologia 2002; 34: 356-9.
45. Busato W, Galindo CC,. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int 2004; 93: 1018-21.
46. Henry R, Morales A, Wyllie MG,. TEMPE: topical eutectic-like mixture for premature ejaculation. Expert Opin Drug Deliv 2008; 5: 251-61.
47. Henry R, Morales A,. Topical lidocaine-prilocaine spray for the treatment of premature ejaculation: a proof of concept study. Int J Impot Res 2003; 15: 277-81.
48. Dinsmore WW, Hackett G, Goldmeier D, et al. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int 2007; 99: 369-75.
49. Dinsmore WW, Wyllie MG,. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int 2009; 103: 940-9.
50. Carson CC, Wyllie MG,. PSD502 increases ejaculatory latency, control and satisfaction: results of a phase IIb, randomized, double-blind, placebo-controlled study in the US and Europe [Abstracts of the Sexual Medicine Society of North America (SMSNA) Fall Meeting. October 16-19, 2008. Toronto, Canada]. J Sex Med 2009; 6 (Suppl. 1): 4-41.
51. Hellstrom W, Carson C, Wyllie M,. PSD 502 appears to be effective in both circumcised and un-circumcised men with premature ejaculation (PE) [Abstracts of the Annual Meeting of the American Urological Association. May 29-June 3, 2010. San Francisco, CA, USA]. J Urol 2010; 183 (Suppl. 4): e576.
52. Choi HK, Xin ZC, Choi YD, et al. Safety and efficacy study with various doses of SS-cream in patients with premature ejaculation in a double-blind, randomized, placebo controlled clinical study. Int J Impot Res 1999; 11: 261-4.
53. Choi HK, Jung GW, Moon KH, et al. Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology 2000; 55: 257-61.
54. Tian L, Xin ZC, Xin H, et al. Effect of renewed SS-cream on spinal somatosensory evoked potential in rabbits. Asian J Androl 2004; 6: 15-8.
55. Salem EA, Wilson SK, Bissada NK, et al. Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med 2008; 5: 188-93.
56. Giuliano F, Hellstrom WJ,. The pharmacological treatment of premature ejaculation. BJU Int 2008; 102: 668-75.
57. Grond S, Sablotzki A,. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43: 879-923.
58. Safarinejad MR, Hosseini SY,. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol 2006; 26: 27-31.
59. Palmer NR,. Tramadol for premature ejaculation. J Sex Med 2009; 6: 299.
60. McMahon CG, McMahon CN, Leow LJ, Winestock CG,. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int 2006; 98: 259-72.
61. Looney C, Thor KB, Ricca D, Marson L,. Differential effects of simultaneous or sequential administration of paroxetine and WAY-100,635 on ejaculatory behavior. Pharmacol Biochem Behav 2005; 82: 427-33.
62. De Jong TR, Pattij T, Veening JG, et al. Citalopram combined with WAY 100635 inhibits ejaculation and ejaculation-related Fos immunoreactivity. Eur J Pharmacol 2005; 509: 49-59.
63. Williamson IJ, Turner L, Woods K, et al. The 5-HT1A receptor antagonist robalzotan enhances SSRI-induced ejaculation delay in the rat. Br J Pharmacol 2003; 138 (Suppl. 1): PO32.